SEC Form 4 · accession 0001225208-17-004785
PFIZER INC · PFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John D Young
Officer — Group President
Period of report
Feb 23, 2017
Accepted (ET)
Feb 27, 2017 · 6:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000078003
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 23, 2017 | M | 51,578 | $21.03 | A | 172,542 | D | |
| Common StockF2 | Feb 23, 2017 | F | 10,282 | $34.06 | D | 162,260 | D | |
| Common StockF3,F4 | Feb 23, 2017 | F | 24,971 | $32.49 | D | 137,289 | D | |
| Common Stock | holding | — | — | — | 1,474 | I | By Rule 16b-3 Plan | |
| Common Stock | holding | — | — | — | 1,373 | I | By Trustee under the Pfizer Share Ownership Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Appreciation RightsF5 | $21.03 | Feb 23, 2017 | M | 51,578 | D | Feb 23, 2017 | Feb 23, 2017 | Common Stock | 51,578 | 0 | D |
| Stock Appreciation RightsF5 | $34.06 | Feb 23, 2017 | A | 146,104 | A | Feb 23, 2022 | Feb 23, 2022 | Common Stock | 146,104 | 146,104 | D |
| Stock Appreciation RightsF6 | $34.06 | Feb 23, 2017 | A | 121,294 | A | Feb 23, 2024 | Feb 23, 2024 | Common Stock | 121,294 | 121,294 | D |
Explanation of responses
- F1The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
- F2The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
- F3The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
- F4Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
- F5The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
- F6The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.